---
title: "Mangoceuticals sells 709,677 shares at $1.55 in $1,100,000 private placement"
url: "https://aibio.space/news/mangoceuticals-sells-709-677-shares-1-55-1-100-000-private-placement/"
publisher: "aibio.space (Biotech Investor Relations News)"
date: "2025-09-02"
section: "Financings"
tickers: "NASDAQ:MGRX"
source: "https://www.sec.gov/Archives/edgar/data/1938046/000149315225012557/form8-k.htm"
summary: "Five accredited investors bought restricted stock under subscription agreements signed August 26, 2025 and August 29, 2025. No underwriters were used."
---

By the aibio.space news desk.

Sources

- [Mangoceuticals, Inc. 8-K (2025-09-02)](https://www.sec.gov/Archives/edgar/data/1938046/000149315225012557/form8-k.htm)

[MGRX](https://aibio.space/companies/mangoceuticals/)

2025-09-02

# Mangoceuticals sells 709,677 shares at $1.55 in $1,100,000 private placement

Tickers [MGRX](https://aibio.space/companies/mangoceuticals/)

Five accredited investors bought restricted stock under subscription agreements signed August 26, 2025 and August 29, 2025. No underwriters were used.

## Key facts

- **Company**: Mangoceuticals, Inc. (NASDAQ: MGRX)

- **News type**: Financings

- **Primary source**: [Mangoceuticals, Inc. 8-K (2025-09-02)](https://www.sec.gov/Archives/edgar/data/1938046/000149315225012557/form8-k.htm)

*A meeting room with a long table and a screen. CC0, via rawpixel. The picture shows the field, not the companies named.*

Mangoceuticals, Inc. sold 709,677 shares of restricted common stock to five accredited investors for $1.55 per share, or a total of $1,100,000, the company said in a [Form 8-K](https://www.sec.gov/Archives/edgar/data/1938046/000149315225012557/form8-k.htm) filed September 2, 2025.

The company signed four subscription agreements with the investors on August 26, 2025 and August 29, 2025. The agreements include piggyback registration rights for one year after the subscription dates. Piggyback rights let investors add their shares to a registration statement the company files for other reasons, so the shares can later be resold publicly.

The shares were not registered with the SEC. Mangoceuticals relied on the private offering exemptions in Section 4(a)(2) and Rule 506 of Regulation D, saying the buyers were accredited investors with access to the kind of information a registration statement would contain. The securities carry a legend restricting transfer.

The company said it used no general solicitation, and that no underwriters or agents were involved. It paid no underwriting discounts or commissions.

[Report an error](https://aibio.space/reputation/#correction)

## Companies in this story

MGRX

Mangoceuticals, Inc.

NASDAQ · United States

Open the starter desk

## More in Financings

Financings

### [INmune Bio raises $4.50 million in registered direct offering with warrants](https://aibio.space/news/inmune-bio-raises-4-50-million-registered-direct-offering-warrants/)

Oct 29, 2026

Financings

### [Lexeo Therapeutics files $300 million shelf registration](https://aibio.space/news/lexeo-therapeutics-files-300-million-shelf-registration/)

Oct 29, 2026

Financings

### [ProKidney files $650 million shelf with $200 million Jefferies sales program](https://aibio.space/news/prokidney-files-650-million-shelf-200-million-jefferies-sales-program/)

Oct 29, 2026

---
Source page: https://aibio.space/news/mangoceuticals-sells-709-677-shares-1-55-1-100-000-private-placement/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Mangoceuticals sells 709,677 shares at $1.55 in $1,100,000 private placement", 2025-09-02, https://aibio.space/news/mangoceuticals-sells-709-677-shares-1-55-1-100-000-private-placement/